ImageneBio Stock (NASDAQ:IMA)

Forecast Ownership Financials Chart

Previous Close

$5.05

52W Range

$3.94 - $9.22

50D Avg

$5.62

200D Avg

$6.02

Market Cap

$56.51M

Avg Vol (3M)

$11.75K

Beta

0.71

Div Yield

IMA Company Profile

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Feb 27, 1998

Website

IMA Performance

IMA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	$3.50M	$9.16M
Operating Income	$-48.45M	$-37.00M	$-75.42M
Net Income	$-52.40M	$-36.57M	$-68.17M
EBITDA	$-48.45M	$-35.47M	$-74.40M
Basic EPS	-	$-1.02	$-1.63
Diluted EPS	-	$-1.02	$-1.63

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
IFRX	InflaRx N.V.
STTK	Shattuck Labs, Inc.
OVID	Ovid Therapeutics Inc.
QNCX	Quince Therapeutics, Inc.
MGX	Metagenomi, Inc. Common Stock
STRO	Sutro Biopharma, Inc.
KLRS	Kalaris Therapeutics Inc
CNTB	Connect Biopharma Holdings Limited
ARTV	Artiva Biotherapeutics, Inc.
CNTX	Context Therapeutics Inc.